ADMA
Market read
The latest filing evidence is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.
Invalidation: The isolated read changes if ADMA's group or a disclosed connection begins moving with it.
Research brief
The latest filing evidence is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.
No thresholded adverse filing evidence is available yet.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“Interest Expense Interest expense for the six months ended June 30, 2026 was $5.5 million, as compared to $3.8 million for the six months ended June 30, 2025, driven by higher average outstanding debt balances under our senior secured credit facility.”10-Q · Aug 5, 2026 ↗
“The increase is primarily related to the capital expenditures associated with the Yield Enhancement project of $1.8 million and the acquisition of the real estate in Boca Raton, FL in the amount of $12.6 million, partially offset by the $1.0 million deposit r…”10-K · Feb 25, 2026 ↗
“This increase of $4.5 million, or 20.4%, was primarily driven by higher employee-related costs, increased software maintenance costs and higher professional and legal fees associated with ongoing litigation and related matters and strategic initiatives suppor…”10-Q · Aug 5, 2026 ↗
Valuation discipline
Price/sales 4.4× · EV/sales 4.4×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 16:00 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for ADMA. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment
10-Q filed 2026-08-05 against the comparable filing from 2025-08-06.
Capital and cash conversion
Capital-spending intensity declined while free-cash-flow margin improved.
Capex, revenue, and operating cash flow are matched to the same reported duration. Reported accounting context, not a forecast or trading recommendation.
No thresholded deterioration was identified.
“Cash Flows The following table sets forth a summary of our cash flows for the periods indicated: Six Months Ended June 30, (in thousands) 2026 2025 Net cash provided by operating activities $ 87,788 $ 1,464 Net cash provided by (used in) investing activities 148 (7,247 ) Net cash used in financing activities (39,546 ) (7,079 ) Net change in cash and cash equivalents 48,390 (12,862 ) Cash and cash equivalents - beginning of period 87,630 103,147 Cash and cash equivalents - end of period $ 136,020 $ 90,285 Net Cash Provided by Operating Activities Cash provided in operations for the six months ended June 30, 2026 was $87.8 million, an increase of $86.3 million from the same period of a year a...”
“26 Index The increase in total revenue was primarily driven by the $19.6 million increase in ASCENIV sales, reflecting continued growth in market acceptance of the product, alongside an increase of $0.7 million in Plasma Collection Centers sales and a $0.4 million increase in intermediates and other products.”
“The improvement in gross margin is primarily driven by favorable product mix in 2026, along with the margin benefits of the yield enhancement manufacturing process optimizations.”
Historical filing backfill generated after the original filing window. It is not part of Jodie's live track record.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“JPM Credit Agreement On August 5, 2025 (the “JPM Closing Date”), we entered into a Credit Agreement (the “JPM Credit Agreement”) with the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent.”
“In December 2018, our former contract manufacturer assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (“Grifols”) as its successor-in-interest, effective January 2019.”
Depended on by
“Our gains were offset by gross realized losses of $3.3 million and $15.0 million, respectively, for the three and nine month periods, from the write-off of equity and warrant investments in Proterra, Inc., The Faction Group LLC, Udacity, Inc., Humanigen, Inc.…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
ADMA is currently a Leader in the organic co-movement group Plasma-Derived Biologics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for ADMA; it is not active in the latest market snapshot.
Context history
No durable theme membership has been observed for this name yet.